INTRODUCTION: Breast cancer is no longer seen as a single disease but rather a multifaceted disease composed of distinct biological subtypes with diverse natural history, clinical, pathological, and molecular features. Recent attention has been directed at the molecular classification of breast cancer. OBJECTIVE: To evaluate the prognostic value of triple-negative subtype in stage II/III breast cancer and to define the role of clinical stage in prognosis of breast cancer. METHODS: We used the immunohistochemical technique to divide 255 cases of breast cancer, stages II and III, into four subtypes according to estrogen receptor/progesterone receptor and Her-2 expression. RESULTS: Triple-negative subtype comprised 76.5% of the cases with 12.3% recurrence rate. Luminal A subtype also carried a poor outcome with 16.7% recurrence rate. CONCLUSION: Triple-negative subtype has the worst overall and disease-free survival in stage II/III breast cancer. Clinical stage is still an independent prognostic factor in the breast cancers of all types.
INTRODUCTION:Breast cancer is no longer seen as a single disease but rather a multifaceted disease composed of distinct biological subtypes with diverse natural history, clinical, pathological, and molecular features. Recent attention has been directed at the molecular classification of breast cancer. OBJECTIVE: To evaluate the prognostic value of triple-negative subtype in stage II/III breast cancer and to define the role of clinical stage in prognosis of breast cancer. METHODS: We used the immunohistochemical technique to divide 255 cases of breast cancer, stages II and III, into four subtypes according to estrogen receptor/progesterone receptor and Her-2 expression. RESULTS: Triple-negative subtype comprised 76.5% of the cases with 12.3% recurrence rate. Luminal A subtype also carried a poor outcome with 16.7% recurrence rate. CONCLUSION: Triple-negative subtype has the worst overall and disease-free survival in stage II/III breast cancer. Clinical stage is still an independent prognostic factor in the breast cancers of all types.
Authors: Dinesh Vyas; Nicolas Lopez-Hisijos; Sulakshana Gandhi; M El-Dakdouki; Marc D Basson; Mary F Walsh; X Huang; Arpita K Vyas; Lakshmi S Chaturvedi Journal: J Nanosci Nanotechnol Date: 2015-09
Authors: Michelle M Noonan; Magdalena Dragan; Michael M Mehta; David A Hess; Muriel Brackstone; Alan B Tuck; Navin Viswakarma; Ajay Rana; Andy V Babwah; Frederic E Wondisford; Moshmi Bhattacharya Journal: Oncotarget Date: 2018-07-10
Authors: Victor García-González; José Fernando Díaz-Villanueva; Octavio Galindo-Hernández; Israel Martínez-Navarro; Gustavo Hurtado-Ureta; Abril Alicia Pérez-Arias Journal: Int J Mol Sci Date: 2018-08-26 Impact factor: 5.923